###### Strengths and limitations of this study

-   This systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

-   Using a comprehensive search strategy, all available and relevant published literature was included for evaluation.

-   There are several fairly consistent methodological flaws present within the trials included in this review: the studies are all small single-centre studies which appear significantly underpowered, there is a consistent failure to clearly prespecify and state a primary outcome measure and the use of concomitant treatments has not been pragmatic.

-   The meta-analysis has been limited by the lack of studies providing adequate outcome data.

Introduction {#s1}
============

Base of thumb osteoarthritis is a common condition that is frequently associated with significant levels of pain, dysfunction and disability.[@R1] The key risk factors include increasing age and female gender.[@R2] The majority of base of thumb pain is managed in primary care or at primary care interface musculoskeletal services by physiotherapists, occupational therapists and general practitioners. The aim of treatment is to improve pain and function, and usual care often encompasses the current guidance from the British Society of Surgery for the Hand advising avoidance of painful activities, analgesia, splintage and steroid injections, with surgery considered to be a 'last resort'.[@R3] Usual care is likely to be highly variable, while there is some evidence which suggests that a majority of patients respond to non-surgical interventions and avoid surgery.[@R4]

There is a lack of high-quality evidence to guide the non-surgical management of base of thumb osteoarthritis,[@R5] and the existing literature demonstrates no clear answer as regard the effectiveness of injection-based interventions such as corticosteroid.[@R7] Steroid injections have been more widely studied in treating shoulder pain in which a short-term benefit over placebo has been demonstrated,[@R8] however concerns remain over their long-term clinical effects.[@R9]

Given this lack of clarity, our aim was to perform a systematic review of the effectiveness of injection-based interventions compared with any comparator/s for base of thumb osteoarthritis in terms of patient-reported outcome measures and to assess the rates of adverse outcomes associated with these interventions.

Methods {#s2}
=======

The systematic review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, using methodology described in the Cochrane Handbook for Systematic Reviews of Interventions. The protocol was developed prospectively and peer reviewed locally before registration on the PROSPERO database (CRD42018095384).

Data sources and searches {#s2-1}
-------------------------

A comprehensive search strategy was created in collaboration with a research librarian (NT) and was designed to capture all relevant articles pertaining to injection-based inventions for base of thumb osteoarthritis (see [online supplementary material 1](#SP1){ref-type="supplementary-material"}). The full search strategy is detailed on the PROSPERO website. The search strategy was applied to the following bibliographic databases from database inception until 22 May 2018: MEDLINE and EMBASE via OVID, CINAHL and SPORTDiscus via EBSCO from database inception until 22 May 2018.
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Inclusion/exclusion criteria {#s2-2}
----------------------------

The inclusion and exclusion criteria were defined prospectively during the protocol stage. Any prospective study relating to an injection-based intervention for base of thumb osteoarthrtitis (trapeziometacarpal) was included. Studies had to contain an injection-based intervention and a comparator/s (ie, both non-randomised controlled trials (non-RCT), and RCTs, including semi-randomised/quasi-randomised, cluster randomised trials and comparative case series). Studies were excluded if patients were under the age of 18 years and if treatment was for inflammatory arthritis such as rheumatoid. Review articles, studies not published as a full article (conference abstracts) and case studies were excluded.

Selection of studies {#s2-3}
--------------------

Duplicates were removed and relevant studies identified from the search were imported into Covidence for screening. Studies were independently screened by title and abstract by two authors (BJFD and MV-B). The references of all included studies and all relevant review articles on the topic were also reviewed to identify other potential studies for inclusion. This was followed by a full-text evaluation of the selected studies from the first selection step by these authors. Disagreement between the two reviewers was solved by consensus involving a third author (NR).

Data extraction {#s2-4}
---------------

Two reviewers (MV-B and BJFD) independently extracted data. Data were extracted using a custom data extraction sheet in Covidence (<http://www.covidence.org>). The custom data extraction sheet was specifically designed to extract data relating to study design, details relating to the interventions undertaken and details regarding the other treatment undergone by trial participants alongside the described interventions. Any inconsistencies between the two reviewers' forms were resolved by consensus discussion. A third review (NR) was available for any disagreement that could not be resolved by this initial discussion.

If data were not available from full-text articles or trial registrations, the authors were contacted to provide this information. If the authors were not contactable as regard additional data, then this aspect of the study was excluded from the data synthesis. If contactable authors did not respond to initial requests, they were sent two subsequent reminders over a minimum of 6 weeks. If there was still no response for the additional data, then this aspect of the study was excluded from the data synthesis.

Risk of bias assessment {#s2-5}
-----------------------

Included studies were assessed for risk of bias by two independent raters (BJFD and MV-B) using the Cochrane Collaboration's tool for assessing risk of bias in randomised trials.[@R11] This followed the description in the Cochrane Handbook for Systematic Review of Interventions, V.5.1 (Part 2: 8.5.1).[@R11] Any disagreements between ratings were resolved by discussion between the raters. A third party (NR) was available in any case where disagreements persisted after discussion.

Outcomes {#s2-6}
--------

Patient-reported pain and function were the primary outcomes of interest, adverse events were also recorded. A priori we defined end points as short term (1 week up to but not including 3 months), medium term (3 months up to and including 6 months) and long term (above 6 months). Where outcome data were available for more than one time point in each time category (short, medium and long term) then the data for the longest time point was used.

Data analysis {#s2-7}
-------------

Descriptive analysis was performed for all demographic, intervention and outcome data to facilitate narrative interpretation and comparison across studies. Details regarding concomitant treatments in the different study arms such as the use of analgesics, splintage and physiotherapy were also recorded. Due to limited data, a direct-comparison meta-analysis was only performed for corticosteroid versus hyaluronic acid for pain (ie, Visual Analogue Scale (VAS) rest and VAS activity) and function (ie, grip strength and tip pinch strength). This was the only area in which data were available for similar time points, outcomes and interventions across two or more studies. Mean difference was used for the meta-analysis of VAS pain and standardised mean difference was used for the meta-analysis of function (grip strength and tip pinch strength). Statistical heterogeneity was determined according to Cochrane interpretation (I² \>75% considerable heterogeneity). Analysis was performed using RevMan using both random-effects and fixed-effects models.

Patient and public involvement {#s2-8}
------------------------------

Patients have not been involved in this review.

Results {#s3}
=======

Study selection {#s3-1}
---------------

A total of 229 studies were identified by the search, after duplicates were removed. After screening by full-text, nine RCTs were identified as eligible for inclusion ([figure 1](#F1){ref-type="fig"}). The number of studies identified and excluded at each stage is detailed in [figure 1](#F1){ref-type="fig"}.

![Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram. (Source) Reproduced from Moher et al, 2009[@R29]](bmjopen-2018-027507f01){#F1}

Study characteristics {#s3-2}
---------------------

Study characteristics of the included trials including the interventions and comparators are provided in [table 1](#T1){ref-type="table"}. Seven RCTs contained two injection therapy treatment groups, while two contained three injection therapy treatment groups. The most common comparison was steroid versus hyaluronic acid (four RCTs).[@R12] Other trials compared placebo with hyaluronic acid,[@R16] steroid versus hyaluronic acid versus placebo,[@R17] steroid versus dextrose,[@R18] steroid versus placebo[@R19] and three different hyaluronic acid injection regimes.[@R20] There was wide variation in terms of the number of injections, drugs and doses used, as well the mode of injection delivery (anatomical as opposed to guided by ultrasound or fluoroscopically). Only three RCTs performed injections under guidance, two of these used fluoroscopic guidance[@R19] and one ultrasound.[@R14] No RCTs compared injection with a non-injection compactor.

###### 

Study characteristics

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                           Year   Journal                                Setting                                              Type of study        Intervention detail                                                                                                                                                        Comparator 1 detail                                                                                            Comparator 2 detail
  -------------------------------- ------ -------------------------------------- ---------------------------------------------------- -------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
  *Bahadir *et al** [@R12]         2009   *Clin Rheumatol*                       Hospital department, Turkey                          Parallel group RCT   *Steroid-X1*: one injection of trimamcinolone 20 mg, anatomical                                                                                                            *HA-X3*: three injections of 5 mg of sodium hyaluronate, anatomical (a week apart)                             N/A

  *Figen Ayhan and Ustün* [@R16]   2009   *Clin Rheumatol*                       Rheumatology department, Turkey                      Parallel group RCT   *Placebo* *(saline)-X1*: one injection of 1 mL saline, anatomical                                                                                                          *HA-X1*: one injection of 8 mg sodium hyaluronate, anatomical                                                  N/A

  *Fuchs *et al** [@R13]           2006   *Osteoarthritis and Cartilage*         Hospital department, Germany                         Parallel group RCT   *Steroid-X3*: three injections of 10 mg triamcinolone, anatomical and 1 week apart                                                                                         *HA-X3*: three injections of 10 mg hyaluronic acid, anatomical and 1 week apart                                N/A

  *Heyworth *et al** [@R17]        2008   *Journal of Hand Surgery* (American)   Orthopaedic hospital, USA                            Parallel group RCT   *Steroid-X1* *+* *p* *lacebo* *(saline)-X1*: two injections, first saline 1 mL and then second 1 week later of 1 mL sodium betamethasone, anatomical                       *HA-X2*: two injections, both 8 mg sodium hyaluronate and 1 week apart, anatomical                             *Placebo* *(saline)-X2*: two injections, both 1 mL saline and 1 week apart, anatomical

  *Jahangiri *et al** [@R18]       2014   *J Orthop Sci*                         Medical department, Iran                             Parallel group RCT   *Steroid-X1* *+* *p* *lacebo* *(saline)-X2*: 2 montly injections of saline 1 mL and then at 3 months injection of 40 mg methylprednisolone and 2% lignocaine, anatomical   *Hypertonic dextrose-X3*:\                                                                                     N/A
                                                                                                                                                                                                                                                                                                                                      0.5 mL of 20% dextrose mixed with 0.5 mL of 2% lidocaine every month for 3 months, anatomical                  

  *Meenagh *et al** [@R19]         2004   *Ann Rheum Dis*                        Hospital Rheumatology department, Northern Ireland   Parallel group RCT   *Steroid-X1*: 5 mg of triamcinolone, guided fluoroscopically                                                                                                               Placebo (saline)-X1: 0.25 mL of 0.9% saline, guided fluoroscopically                                           N/A

  *Monfort *et al** [@R14]         2015   *Joint Bone Spine*                     Hospital Rheumatology department, Spain              Parallel group RCT   *Steroid-X3*: 0.5 cm^3^ of betamethasone disodium phosphate 1.5 mg and betamethasone acetate 1.5 mg at weekly intervals for 3 weeks, ultrasound guided                     *HA-X3*: 0.5 cm^3^ contained 5 mg of sodium hyaluronate at weekly intervals for 3 weeks, ultrasound guided     N/A

  *Roux *et al** [@R20]            2007   *Joint Bone Spine*                     Hospital Rheumatology department, France             Parallel group RCT   *HA-X1*: 1 mL containing 8 mg of hyaluronic acid injected once, guided fluoroscopically                                                                                    *HA-X2*: 1 mL containing 8 mg of hyaluronic acid injected twice at weekly intervals, guided fluoroscopically   *HA-X3*: 1 mL containing 8 mg of hyaluronic acid injected three times at weekly intervals, guided fluoroscopically

  *Stahl *et al** [@R15]           2005   *J Clin Rheumatol*                     Hand surgery unit, Israel                            Parallel group RCT   *Steroid-X1*: one injection of 40 mg methylprednisolone, anatomical                                                                                                        *HA-X1*: 1 mL containing 15 mg of hyaluronic acid injected once, anatomical                                    N/A
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N/A, not available; RCT, randomised controlled trial.

[Table 2](#T2){ref-type="table"} details the inclusion and exclusion criteria, the basic demographics of the intervention and comparator groups as well as details relating to the outcome data. Inclusion and exclusion criteria were highly variable. All trials were solely related to adults with symptomatic base of thumb osteoarthritis, most specified a particular radiographic grading as an inclusion criterion, either the classification by Eaton and Littler or Kellgren and Lawrence were used. Two trials did not specify a particular grade of base of thumb osteoarthritis.[@R17] One trial specified the need for bilateral symptoms as one side received steroid and the other placebo injection.[@R16] Two trials were exclusively of females.[@R12] The remaining trials included a minority of men, while one did not state the gender breakdown.[@R14] The mean age of participants was close to 60 years, other than the study by Monfort *et al*,[@R14] which had a mean age of 38.5 years. Only three trials contained adequate data within the published text for undertaking further analysis.[@R12] We contacted the authors of the remaining six studies and one author responded to supply a complete data set.[@R15]

###### 

Details of study participants demographics, inclusion/exclusion criteria and whether data were provided

  Author                           Year   Inclusion criteria---all base of thumb osteoarthritis                                                                                            Exclusion criteria                                                                                                                                                        Number of participants   Mean age of participants   Sex of participants    Data comments
  -------------------------------- ------ ------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ -------------------------- ---------------------- ---------------------------------------------------------------------------------
  *Bahadir *et al** [@R12]         2009   Eaton-Littler grade 2 or 3                                                                                                                       Inflammatory arthritis, trauma, carpal tunnel, previous injection                                                                                                         40                       61.9                       40 females             Adequate data within original publication to enable potential meta-analysis.
  *Figen Ayhan and Ustün* [@R16]   2009   Bilateral symptoms with failed prior treatment, Eaton-Littler grade 1--4                                                                         Injection within last 6 months, trauma, inflammatory arthritis, joint infection                                                                                           66                       62.6                       66 females             Incomplete outcome data and this was not provided by the authors on request.
  *Fuchs *et al** [@R13]           2006   Aged between 44 and 80 years with radiographic osteoarthritis symptomatic for at least 6 months                                                  Alcohol/drug abuse, recent injection, inflammatory arthritis, uncontrolled diabetes, joint infection                                                                      56                       60.3                       45 female, 11 males    Incomplete outcome data and this was not provided by the authors on request.
  *Heyworth *et al** [@R17]        2008   Symptomatic osteoarthritis without need for radiographic confirmation                                                                            More than two previous injections, pregnancy, previous surgery, trauma to joint, no benefit from previous steroid injection, inflammatory arthritis                       60                       63                         52 females, 8 males    Incomplete outcome data and this was not provided by the authors on request.
  *Jahangiri *et al** [@R18]       2014   Aged over 40 with symptoms for over 3 months and pain \>30 mm VAS, radiographic grade 2 and above Eaton-Littler                                  Inflammatory arthritis, tendon pain, joint infection, use of splint or NSAIDs, pregnancy, injection within last 6 months                                                  60                       63.5                       44 females, 16 males   Incomplete outcome data and this was not provided by the authors on request.
  *Meenagh *et al** [@R19]         2004   Symptomatic and satisfying ACR classification of hand osteoarthritis                                                                             Inflammatory arthritis, previous thumb trauma, previous injection to either thumb base                                                                                    40                       60                         36 females, 4 males    Incomplete outcome data and this was not provided by the authors on request.
  *Monfort *et al** [@R14]         2015   Symptomatic for at least 90 days, requiring analgesics, radiographic confirmation with at least grade 1 Kellgren-Lawrence                        Pregnancy, severe renal/liver disease, injection within last 3 months, previous thumb surgery, previous physical therapy                                                  88                       38.5                       Not stated             Adequate data within original publication to enable potential meta-analysis.
  *Roux *et al** [@R20]            2007   Symptomatic with VAS \<40 mm, refractory to other therapeutic interventions, radiographic confirmation with at least grade 1 Kellgren-Lawrence   Symptomatic osteoarthritis in other digits, blood coagulation disorder, hand trauma, hand infection, steroid injection within 6 months or any hyaluronic acid injection   42                       65.6                       38 females, 4 males    Adequate data within original publication to enable potential meta-analysis.
  *Stahl *et al** [@R15]           2005   Symptomatic grade 2 according to Eaton-Littler classification                                                                                    None                                                                                                                                                                      52                       62                         46 females, 6 males    Incomplete outcome data and this was kindly provided by the authors on request.

ACR, American College of Rheumatology; NSAID, non-steroidal anti-inflammatory drug; VAS, Visual Analogue Scale.

[Table 3](#T3){ref-type="table"} details the study outcomes, time points and a summary of results including adverse events. Only two of the nine trials clearly specified a primary outcome.[@R19] The VAS for base of thumb pain was used by all trials, however it was used in several different formats such as the standard VAS (average of pain and activity), VAS (rest), VAS (activity), VAS (pressure) and VAS (average of pain, activity and pressure). The majority of trials final follow-up was at 6 months, the exceptions to this being the studies by Bahadir *et al* [@R12] and Roux *et al* [@R20] which followed participants until 12 and 3 months, respectively.

###### 

Details of study outcomes, time points and a summary of results

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                           Year   Outcomes (primary in italics if present)                                                                                Time points                                              Effect measures---mean difference (95% CI) in short term, medium term, long term                 Summary of results and adverse events
  -------------------------------- ------ ----------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Bahadir *et al** [@R12]         2009   VAS (activity), tip pinch strength, grip strength, Duruoz Hand Index                                                    Baseline, 1 month, 3 months, 6 months, 12 months         VAS (activity) −1.60 (−3.21 to 0.01), −2.20 (−3.45 to --0.95), −1.10 (−2.37 to 0.17)\            Greater statistically significant improvement in VAS with corticosteroid than with hyaluronic acid at 1 month and 6 months. No adverse events.
                                                                                                                                                                                                                           Tip pinch strength 1.90 (0.60 to 3.20), 1.10 (−0.17 to 2.37), 1.10 (−0.11 to 2.31)\              
                                                                                                                                                                                                                           Grip strength 9.60 (2.03 to 17.17), 6.40 (−0.05 to 12.85), 4.80 (−2.46 to 12.06)\                
                                                                                                                                                                                                                           Duruoz Hand Index −10.20 (−17.24 to --3.16), −10.10 (−16.77 to --3.43), −3.80 (−11.57 to 3.97)   

  *Figen Ayhan and Ustün* [@R16]   2009   VAS (average of rest/activity/pressure), tip pinch strength, tripod pinch strength, key pinch strength, Dreiser Index   Baseline, 6 weeks, 6 months                              Not estimable from available data                                                                No statistically significant difference in outcomes at any time point. No adverse events.

  *Fuchs *et al** [@R13]           2006   VAS pain, tip pinch strength, key pinch strength, range of movement                                                     Baseline, 3 weeks, 14 weeks, 26 weeks                    Not estimable from available data                                                                Statistically significant superiority of corticosteroid over hyaluronic acid at 2 and 3 weeks time point in terms of pain relief. No causal adverse events.

  *Heyworth *et al** [@R17]        2008   VAS pain, tip pinch strength, grip strength, key pinch strength, DASH, range of motion (MCPJ)                           Baseline, 2 weeks, 4 weeks, 12 weeks, 26 weeks           Not estimable from available data                                                                No statistically significant difference between groups at most time points. No adverse events.

  *Jahangiri *et al** [@R18]       2014   VAS (pressure), lateral pinch strength, VAS (activity), hand function (HAQ-DI)                                          Baseline, 1 month, 2 months, 6 months                    VAS (pressure) data not provided for short term, 1.1 (0.2 to --2.0) in medium term\              Corticosteroid group had statistically significant reduction in VAS (pressure) at 1 month vs dextrose, while dextrose demonstrated statistically significant reduction in VAS (pressure) at 6 months vs corticosteroid. No adverse events.
                                                                                                                                                                                                                           VAS (activity) 1.0 (0.1 to 2.0), 1.1 (0.2 to 2.0)\                                               
                                                                                                                                                                                                                           Lateral pinch strength 1.1 (−0.8 to 3.1), 0.8 (−1.3 to 2.9)\                                     
                                                                                                                                                                                                                           HAQ-DI 1.0 (0.2 to 1.9), 1.0 (0.2 to 1.8)                                                        

  *Meenagh *et al** [@R19]         2004   *VAS (pain)*, joint tenderness, patient global assessment, physician global assessment, joint stiffness                 Baseline, 1 month, 3 months, 6 months                    Joint tenderness −1.00 (−1.80 to --0.20), −2.00 (−3.92 to --0.08)\                               No statistically significant difference between groups at all time points. No adverse events.
                                                                                                                                                                                                                           Patient global assessment −2.00 (−3.92 to --0.08), −2.00 (−3.92 to --0.08)\                      
                                                                                                                                                                                                                           Physician global assessment −2.00 (−3.92 to --0.08), −1.00 (−1.27 to --0.73)\                    
                                                                                                                                                                                                                           Joint stiffness −1.00 (−1.27 to --0.73), −1.00 (−1.27 to --0.73)\                                
                                                                                                                                                                                                                           VAS (pain) not estimable from available data                                                     

  *Monfort *et al** [@R14]         2015   VAS (rest), Dreiser Index, PCS-36, MCS-36                                                                               Baseline, 1 week, 2 weeks, 1 month, 2 months, 6 months   VAS (rest) −0.56 (−1.58 to 0.46), 0.55 (−0.51 to 1.61)\                                          No statistically significant difference between groups at all time points in VAS and Dreiser Index. No adverse events.
                                                                                                                                                                                                                           Dreiser Index 0.00 (−2.24 to 2.24), not estimable from available data at medium term\            
                                                                                                                                                                                                                           PCS-36 0.00 (−2.24 to 2.24) at medium term\                                                      
                                                                                                                                                                                                                           MCS-36 0.00 (−2.24 to 2.24) at medium term                                                       

  *Roux *et al** [@R20]            2007   *VAS (rest)*, Dreiser Index                                                                                             Baseline, 1 month, 3 months                              HA1 vs HA2\                                                                                      No statistically significant difference in outcomes between groups at all time points. No adverse events.
                                                                                                                                                                                                                           VAS (rest) −1.90 (−21.48 to 17.68), 3.60 (−16.60 to 23.80)\                                      
                                                                                                                                                                                                                           Dreiser Index −1.70 (−7.71 to 4.31), 0.00 (−2.24 to 2.24)\                                       
                                                                                                                                                                                                                           HA1 vs HA3\                                                                                      
                                                                                                                                                                                                                           VAS (rest) −0.06 (−0.84 to 0.73), 3.60 (−16.60 to 23.80)\                                        
                                                                                                                                                                                                                           Dreiser Index −1.70 (−7.71 to 4.31), −1.70 (−7.71 to 4.31)\                                      
                                                                                                                                                                                                                           HA2 vs HA3\                                                                                      
                                                                                                                                                                                                                           VAS (rest) 0.53 (−0.29 to 1.34), 0.53 (−0.29 to 1.34)\                                           
                                                                                                                                                                                                                           Dreiser Index −1.70 (−7.71 to 4.31), −1.70 (−7.71 to 4.31)                                       

  *Stahl *et al** [@R15]           2005   Tip pinch strength, tripod pinch strength, key pinch strength, grip strength, VAS (rest), VAS (activity)                Baseline, 1 month, 3 months, 6 months                    VAS (activity) 0.35 (−0.90 to 1.60), −0.30 (−1.64 to 1.04)\                                      No statistically significant difference in outcomes between groups at all time points. No adverse events.
                                                                                                                                                                                                                           VAS (rest) −0.27 (−0.81 to 0.28), 0.25 (−1.09 to 1.59)\                                          
                                                                                                                                                                                                                           Tip pinch strength −0.77 (−1.43 to --0.11), −0.33 (−0.96 to 0.30)\                               
                                                                                                                                                                                                                           Tripod pinch strength −0.79 (−1.72 to 0.14), −0.45 (−1.34 to 0.44)\                              
                                                                                                                                                                                                                           Key pinch strength −1.19 (−2.43 to 0.05), −1.02 (−2.14 to 0.10)\                                 
                                                                                                                                                                                                                           Grip strength −0.33 (−0.96 to 0.30), −0.33 (−0.96 to 0.30)                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DASH, Disabilities of the Arm, Shoulder and Hand; HA1, one HA injection group; HA2, two HA injections group; HAQ-DI, Health Assessment Questionnaire - Disability Index; MCPJ, metacarpophalangeal joint; MCS, mental component summary of the SF-36; PCS, physical component summary of the SF-36; SF-36, short form 36 health survey; VAS, Visual Analogue Scale.

[Table 4](#T4){ref-type="table"} describes the concomitant treatment undergone by the trial participants broken down into analgesia, splint use and other. Some trials made little mention of concomitant therapies, for example, Stahl *et al* [@R15] made no mention of other treatments while Meenagh *et al* [@R19] only mentioned that a splint was used for 48 hours after the injection. The approach to analgesics was highly variable. Meenagh *et al* [@R19] did not mention analgesics Monfort *et al* [@R14] and Roux *et al* [@R20] allowed all analgesics while all the other trials prohibited the use of analgesics in a highly variable manner. The approach to splintage was also highly variable. Both Roux *et al* [@R20] and Fuchs *et al* [@R13] made no change to splint usage. While Jahangiri *et al* [@R18] excluded patients who used splints and Bahadir *et al* [@R12] prohibited the use of splints. Heyworth *et al* [@R17] and Meenagh *et al* [@R19] specified the use of a splint for a short period after injection therapy, but did not describe splint usage outside of this window.[@R19] Monfort *et al* [@R14] Stahl *et al* [@R15] and Figen Ayhan and Ustün[@R16] all made no mention of splint usage. Only two trials made any mention of hand therapy, Jahangiri *et al* [@R14] instructed patients not to undergo any therapy, while Monfort *et al* [@R18] excluded patients who had undergone hand therapy.

###### 

Details of concomitant treatment alongside injection therapy

  Author                           Year   Analgesia                                                                                                                                                                                                                   Splintage                                                                                                                            Other
  -------------------------------- ------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Bahadir *et al** [@R12]         2009   No concomitant analgesia allowed in all treatment groups                                                                                                                                                                    No splint used in all groups. No mention of how many had used splint regularly before study period.                                  Not mentioned.
  *Figen Ayhan and Ustün* [@R16]   2009   No analgesia allowed for 2 weeks before injection and not mentioned what was allowed after injection therapy                                                                                                                No mention of splint usage.                                                                                                          No mention of other therapy after injection therapy.
  *Fuchs *et al** [@R13]           2006   Only paracetamol allowed and all other analgesics stopped in all groups                                                                                                                                                     No change in use of splintage and not recorded in terms of details.                                                                  Not mentioned.
  *Heyworth *et al** [@R17]        2008   Two-week 'wash-out' period before injection during which no use of NSAIDs was allowed for all groups                                                                                                                        Hand-based neoprene thumb spica splint used for minimum of 22 hours per day for the 2 weeks after injection therapy in all groups.   Spint was allowed as necessary and NSAIDs were allowed in all groups 2 weeks after the injection therapy.
  *Jahangiri *et al** [@R18]       2014   Patients using NSAIDs excluded. Participants were instructed not to use analgesic medications.                                                                                                                              Patients using splints excluded. Participants in the study were instructed not to use a splint.                                      All the patients were asked to return gradually to normal activities but to avoid pain-provoking physical stresses, especially within the first 48 hours after injection. Participants were instructed not to undergo physiotherapy.
  *Meenagh *et al** [@R19]         2004   Not mentioned                                                                                                                                                                                                               Splinted for 48 hours after injection therapy in all groups.                                                                         Not mentioned.
  *Monfort *et al** [@R14]         2015   Medications were allowed and those used within 30 days before screening and throughout the study period, including paracetamol (maximum 3 g/day) as rescue medication, were recorded in a diary card                        Not mentioned.                                                                                                                       Patients excluded if physical therapy performed by a physiotherapist at home or in a specialised centre.
  *Roux *et al** [@R20]            2007   Treatment had not been modified for at least 3 months (analgesics/NSAIDs/osteoarthtis drugs). Patients were in failure of treatment and usual treatments (NSAIDs, analgesics) remained unchanged during the study period.   Treatment with splints had not been modified for at least 3 months. Splint treatment remained unchanged during the study period.     No other treatment was modified during study period. Therapy not mentioned specifically.
  *Stahl *et al** [@R15]           2005   Not mentioned                                                                                                                                                                                                               Not mentioned.                                                                                                                       Not mentioned.

NSAID, non-steroidal anti-inflammatory drug.

Adverse events {#s3-3}
--------------

All trials reported that no adverse events had occurred as a result of any trial interventions, thus demonstrating the general safety of injection-based therapies. However, the absence of published study protocols and published details regarding what precisely constituted an 'adverse event' surveillance does make it difficult to be specific as to what this actually means.

Risk of bias within studies and across studies {#s3-4}
----------------------------------------------

Overall, the degree of bias was fairly heterogeneous across all bias domains. Only one trial was at high risk of bias in terms of sequence generation due to the use of a sequence generated by the patient's hospital number.[@R16] Blinding of participants was not possible in the trials by Bahadir *et al* and Roux *et al* due to the different number of injections received by both treatment groups,[@R12] while the injecting clinician was not blinded in the trial by Heyworth *et al*.[@R17] One study was at high risk of bias regarding incomplete outcome data due to a significantly greater loss to follow-up in the steroid injection group.[@R14] The risk of bias summary is shown in [figure 2](#F2){ref-type="fig"} and the risk of bias graph is included as [online supplementary file 2](#SP2){ref-type="supplementary-material"}. Other sources of bias included the use of a single individual performing injections in a single centre,[@R12] industry funding,[@R13] the 'random' exclusion of a large group of patients,[@R18] underpowering by not meeting study's own stated number of patients,[@R19] a lack of control group[@R20] and the role of industry is providing sodium hyaluronate without charge.[@R15]
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![Risk of bias summary. Review the authors\' judgements about each risk of bias item for each included study.](bmjopen-2018-027507f02){#F2}

Results of individual studies and synthesis of results {#s3-5}
------------------------------------------------------

The results of the individual trials are summarised in [table 3](#T3){ref-type="table"}. Due to limited data, meta-analysis was only performed for the comparison of corticosteroid versus hyaluronic acid for pain (ie, VAS rest and VAS activity) and function (ie, grip strength and tip pinch strength) ([figures 3--6](#F3 F4 F5 F6){ref-type="fig"}).

![Forest plot of comparison: corticosteroid vs hyaluronic acid, outcome: pain---VAS (activity).](bmjopen-2018-027507f03){#F3}

![Forest plot of comparison: corticosteroid vs hyaluronic acid, outcome: pain---VAS (rest).](bmjopen-2018-027507f04){#F4}

![Forest plot of comparison: corticosteroid vs hyaluronic acid, outcome: function---grip strength.](bmjopen-2018-027507f05){#F5}

![Forest plot of comparison: corticosteroid vs hyaluronic acid, outcome: function---tip pinch strength.](bmjopen-2018-027507f06){#F6}

Pain {#s3-6}
----

### Corticosteroid versus hyaluronic acid {#s3-6-1}

Bahadir *et al* [@R12] demonstrated that steroid was superior to hyaluronic acid in terms of pain (VAS (activity)) in the medium term (MD −2.20, 95% CI −3.45 to −0.95) but not at long term. Fuchs *et al* [@R13] showed a short term (2 and 3 weeks) superiority of steroid over hyaluronic acid in terms of pain (VAS). The studies by Heyworth *et al*,[@R17] Monfort *et al* [@R14] and Stahl *et al* [@R15] showed no difference in pain in the short and medium term ([figures 3 and 4](#F3 F4){ref-type="fig"}).

Meta-analysis of the studies by Bahadir *et al* and Stahl *et al* showed a small reduction in pain (VAS (activity)) in medium term in those participants who received corticosteriod compared with control, however there was no difference in the short or long term ([figure 3](#F3){ref-type="fig"}). Meta-analysis of the studies by Monfort *et al* and Stahl *et al* demonstrated no difference in pain (VAS (rest)) between corticosteroid and hyaluronic acid in the short and medium term ([figure 4](#F4){ref-type="fig"}).

### Corticosteroid versus placebo {#s3-6-2}

The studies by Heyworth *et al* [@R17] and Meenagh *et al* [@R19] demonstrated no difference in pain (VAS) in the short and medium term, however no further analysis was possible due to the incomplete data provided.

### Hyaluronic acid versus placebo {#s3-6-3}

The studies by Heyworth *et al* [@R17] and Figen Ayhan *et al* [@R16] demonstrated no difference in pain in the short and medium term, again no further analysis was possible due to the incomplete data provided.

### Corticosteroid versus dextrose {#s3-6-4}

Jahangiri *et al* found that the corticosteroid group had a reduction in VAS (rest) in the short term versus dextrose, however there was no difference in pain (VAS (activity)).[@R18] Jahangiri *et al* also demonstrated a reduction in pain (VAS (pressure)) in the medium term in the dextrose group compared with the corticosteroid group,[@R18] however there was no difference in pain (VAS (activity)) in the medium term.

### Hyaluronic acid comparisons {#s3-6-5}

Roux *et al* demonstrated no difference in pain (VAS (rest)) in the short term with one versus two versus three hyaluronic acid injections in the short and medium term.[@R20]

Function (tip pinch strength and grip strength) {#s3-7}
-----------------------------------------------

### Corticosteroid versus hyaluronic acid {#s3-7-1}

The studies by Heyworth *et al*, Monfort *et al* and Stahl *et al* showed no difference in hand function in the short term and medium term.[@R14] Bahadir *et al* demonstrated that steroid was superior to hyaluronic acid in terms of function in the short and medium term (Duruoz Hand Index),[@R12] but no differences in tip pinch strength and grip strength in the long term.[@R12]

Meta-analysis of the results of the Stahl *et al* and Bahadir *et al* studies demonstrated no differences in tip pinch strength and grip strength in the short term and medium term ([figures 5 and 6](#F5 F6){ref-type="fig"}).[@R12]

### Corticosteroid versus placebo {#s3-7-2}

The studies by Heyworth *et al* and Meenagh *et al* demonstrated no difference in function in the short and medium term, however no further analysis was possible due to the incomplete data provided.[@R17]

### Hyaluronic acid versus placebo {#s3-7-3}

The studies by Heyworth *et al* and Figen Ayhan *et al* demonstrated no difference in function in the short and medium term, again no further analysis was possible due to the incomplete data provided.[@R16]

### Corticosteroid versus dextrose {#s3-7-4}

Jahangiri *et al* demonstrated no difference in function in the short term and medium term.[@R18]

### Hyaluronic acid comparisons {#s3-7-5}

Roux *et al* demonstrated no difference in function (Dreiser Index) in the short and medium term with one versus two versus three hyaluronic acid injections.[@R20]

Discussion {#s4}
==========

The key finding of this systematic review is that the current evidence is equivocal regarding the use of injection therapy in base of thumb osteoarthritis, both in terms of which injection-based therapy is the most effective and in terms of whether any injection-based therapy is more effective than other non-injection-based interventions. It is of interest that there is no prospective evidence in which an injection-based therapy is compared with a non-injection-based intervention.

The existing evidence base suggests that a majority of patients who present with painful base of thumb osteoarthritis avoid surgical intervention.[@R4] However, it remains unclear as to which specific non-surgical interventions add value due to the significant methodological problems with the studies that have been carried out in this area.[@R6] As a result, it is likely that the non-operative management of base of thumb osteoarthritis is highly variable, much as the surgical management appears to be.[@R24] In the UK, corticosteroid injection is widely used, although data documenting the precise economic costs of this practice is lacking.[@R25]

A previous robust systematic review by Kroon *et al* has reached similar conclusions to those of our study.[@R7] However, by obtaining additional data from the authors we were able to undertake a meta-analysis demonstrating a reduced VAS pain on activity with corticosteroid versus hyaluronic acid (MD −1.32, 95% CI −2.23 to −0.41) in the medium term, this being a novel finding. In this context, it is particularly difficult to justify the use of the more expensive hyaluronic acid over corticosteroid in treating base of thumb osteoarthritis. There are some other key methodological differences between our study and the review by Kroon *et al*. We excluded studies which had not been published in full after peer review, while these were included by Kroon *et al*. We have also described the approach of trials to concomitant therapies in significantly greater detail as discussed below. Broadly we feel that our findings validate and add to this previous work by Kroon *et al*. Overall, the justification for future research in this area remains strong, as it is imperative to determine whether such widely used interventions provide any clinically meaningful advantages over placebo.

Our review has summarised the way in which trials have handled concomitant treatments in detail and we feel this is of key importance given the way in which patients with base of thumb osteoarthritis are managed in the real world. Several studies did not even record which concomitant treatments patients had undergone before or after study interventions, while concomitant treatments were frequently managed in a rather artificial non-pragmatic manner. This can be addressed by a more pragmatic trial design as described in the recently published HIT trial protocol that has addressed the problem of concomitant treatments in hip osteoarthritis by combining injection-based interventions with 'best current treatment' and ensuring that all analgesic use is recorded; in this way, the concomitant treatments become more homogenous between patients and any differences can be taken into account.[@R26] Generally, patients in the real world are not advised to stop taking other analgesics before or after receiving an injection,[@R27] however in several of the included studies in this review this is precisely what was done. A similar argument can be made about splint usage, as generally most patients have received some form of guidance about splint usage for symptom control before undergoing any form of injection-based intervention. Certainly, at a minimum the use of all concomitant treatments should be recorded before and after trial interventions have been administered.

Only two included studies used a specific symptom threshold for inclusion, Jahangiri *et al* [@R18] included those with a VAS \>30 mm while Roux *et al* [@R20] excluded those with a VAS \>40 mm. The current Osteoarthritis Research Society International (OARSI) guidelines advise having a minimum cut-off for inclusion in terms of pain or function, obviously using pain or functional measures may depend on the primary outcome measure.[@R28] This factor is another potential contributant to negative trial results as by failing to have a minimum cut-off for trial inclusion, trials are likely to have been including participants with relatively minimal levels of symptoms which makes it less likely that a clinically meaningful difference in outcomes can be achieved.

This review has highlighted several important aspects of trial methodology which must be considered carefully in the planning and design of future research. Future trials should clearly prespecify a primary outcome measure and ideally consider current guidelines relating to clinical trials in osteoarthritis.[@R28] Trials should involve multiple centres and be adequately powered, the current evidence base consists of virtually exclusively small single-centre studies. It is also important to ensure that the current management of base of thumb osteoarthritis is assessed in some detail, as this is also an area in which little has been published. There may be considerable variations in practice in terms of which injection therapies are used and how the injection is delivered, and in terms of the threshold for injection. This review has highlighted how variable the approach of different studies has been to dealing with the issue of concomitant or previous treatments, this also presents a challenge to researchers in the future. As discussed above, it appears best to adopt a pragmatic approach based on an assessment of what is generally deemed to be standard best practice.

Limitations {#s4-1}
-----------

The main limitations to this systematic review and meta-analysis are the limitations intrinsic to the included studies, which are detailed above. There are several fairly consistent methodological flaws present within the trials included in this review; the studies are all small single-centre studies which appear significantly underpowered, there is a consistent failure to clearly prespecify and state a primary outcome measure and the use of concomitant treatments has not been pragmatic. The meta-analysis has been significantly limited by a lack of adequate outcome data.

Conclusions {#s5}
===========

Current evidence is equivocal regarding the use of injection therapy in base of thumb osteoarthritis, both in terms of which injection-based therapy is the most effective and in terms of whether any injection-based therapy is more effective than other non-injection-based interventions. Given limited understanding of both the short-term and long-term effects, there is a need for large, methodologically robust multicentre RCTs investigating the commonly used injection therapies and comparison made with other therapeutic options and placebo.
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